Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17537229 | 0.83 | KDM4E (0.48) | PDE4AUSP2SLCO1B1KDM4ELMNA | |
| SCHEMBL13010838 | 0.82 | KDM4E (0.47) | PDE4AUSP2SLCO1B1KDM4ELMNA | |
| SCHEMBL13010836 | 0.82 | KDM4E (0.47) | PDE4AUSP2SLCO1B1KDM4ELMNA | |
| SCHEMBL468790 | 0.80 | PDE4A (0.50) | PDE4AUSP2SLCO1B1KDM4ELMNA | |
| SCHEMBL468705 | 0.80 | PDE4A (0.50) | PDE4AUSP2SLCO1B1KDM4ELMNA | |
| SCHEMBL15872065 | 0.80 | PDE4A (0.50) | PDE4AUSP2SLCO1B1KDM4ELMNA | |
| SCHEMBL27182003 | 0.80 | PDE4A (0.50) | PDE4AUSP2SLCO1B1KDM4ELMNA | |
| SCHEMBL468798 | 0.80 | PDE4A (0.50) | PDE4AUSP2SLCO1B1KDM4ELMNA | |
| SCHEMBL13026582 | 0.80 | PDE4A (0.50) | PDE4AUSP2SLCO1B1KDM4ELMNA | |
| SCHEMBL11225324 | 0.80 | PDE4A (0.50) | PDE4AUSP2SLCO1B1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0253226-B1 | AQUEOUS ALCALINE INJECTABLE SOLUTION OF TORASEMID READY FOR USE AND PROCESS FOR PREPARATION THEREOF | Roche Diagnostics GmbH (DE) | 1990-06-06 | — | — | EP | claimed |
| EP-0253226-A1 | Aqueous alcaline injectable solution of torasemid ready for use and process for preparation thereof | Roche Diagnostics GmbH (DE) | 1988-01-20 | — | — | EP | claimed |
| EP-3318555-B1 | BIFUNCTIONAL CHELATING AGENTS | BWXT MEDICAL LTD (CA) | 2023-08-16 | — | — | EP | disclosed |
| EP-3318555-A1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc. (CA) | 2018-05-09 | — | — | EP | disclosed |
| EP-2536691-B1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-11-22 | — | — | EP | disclosed |
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| EP-2619210-A1 | PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE | Nordion (Canada) Inc. (CA) | 2013-07-31 | — | — | EP | disclosed |
| EP-2536691-A1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc. (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-20120095185-A1 | PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE | NORDION (CANADA) INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| WO-2012037648-A1 | PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE | NORDION (CANADA) INC. (CA) | 2012-03-29 | — | — | WO | disclosed |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011100829-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. (CA) | 2011-08-25 | — | — | WO | disclosed |
| EP-0253226-B1 | AQUEOUS ALCALINE INJECTABLE SOLUTION OF TORASEMID READY FOR USE AND PROCESS FOR PREPARATION THEREOF | Roche Diagnostics GmbH (DE) | 1990-06-06 | — | — | EP | disclosed |
| US-4861786-A | Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use | BOEHRINGER MANNHEIM GMBH (DE) | 1989-08-29 | — | — | US | disclosed |
| EP-0253226-A1 | Aqueous alcaline injectable solution of torasemid ready for use and process for preparation thereof | Roche Diagnostics GmbH (DE) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | FCGRT, C1QBP, H1-2 | PDE4A 4567/4885USP2 2641/4885SLCO1B1 106/4885 |
| US-20120095185-A1 | PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE | TBCA, UBE2G2, COPG2 | PDE4A 4630/4885USP2 232/4885SLCO1B1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.